Latest News and Press Releases

MELBOURNE, Australia and SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...

Neurona Doses First Patient in Phase 1/2 Trial of NRTX-1001 Cell Therapy in Adults with Drug-Resistant, Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

Centre for Neuro Skills launched a redesigned website with intuitive, accessible tools for brain injury survivors, their families and healthcare providers.

Longeveron CEO Wa’el Hashad will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference.

SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) -- Sutter Health today broke ground on the new Sutter Advanced Neuroscience Complex at Mission Bernal – a major milestone in expanding access to...

Trethera enlists leading expert in demyelinating diseases to advance TRE-515, a first-in-class drug with FDA Orphan Drug status for ADEM and optic neuritis

Montara Therapeutics received a research grant from The Michael J. Fox Foundation for the development of new therapies targeting LRRK2.

EXTON, PA, May 15, 2025 (GLOBE NEWSWIRE) -- The treatment landscape for generalized myasthenia gravis (gMG) has entered a new era of therapeutic innovation. Since 2022, seven novel targeted...

COMMUNIQUÉ DE PRESSE LE MASITINIB MONTRE DES EFFETS NEUROPROTECTEURS PROMETTEURS DANS UN MODÈLE DE MALADIE NEURODÉGÉNÉRATIVE INDUITE PAR LE SYSTÈME IMMUNITAIRE UNE NOUVELLE PUBLICATION DANS LA...

PRESS RELEASE MASITINIB SHOWS PROMISING NEUROPROTECTIVE EFFECTS IN NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE MODEL A NEW PUBLICATION IN THE SCIENTIFIC JOURNAL PLOS ONE, SHOWS THAT MASITINIB CAN...